Natalie Nokoff, MD
Transgender individuals are people whose gender identity
does not match their birth sex and are a growing and understudied population.
Transgender youth in early puberty may be prescribed a “puberty blocker” that
shuts down their body’s production of sex hormones and prevents unwanted
secondary sex characteristics from developing. Then, later in adolescence,
hormones such as testosterone are often prescribed as a part of their
transition to give individuals the secondary sex characteristics that align with
their gender identity. Dr. Nokoff is studying the effects of pubertal blockade
and testosterone therapy in female-to-male transgender adolescents on insulin
sensitivity and vascular health.